Turkish Alzheimer Prevalence Study

https://www.neurodegenerationresearch.eu/survey/turkish-alzheimer-prevalence-study/

Title of the cohort

Turkish Alzheimer Prevalence Study

Acronym for cohort

Name of Principal Investigator

Title	Professor
First name	Murat
Last name	Emre

Address of institution where award is held

Institution	Istanbul University Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit
Street Address	Millet Cad. Capa, Sehremini
City	Istanbul
Postcode	34093

Country

Turkey

Website

www.itfnoroloji.org

Contact email

Funding source

Pharma industry

1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer’s disease and other dementias

When studies on the above condition(s) are expected to become possible

Already possible

2a. Stated aim of the cohort

Prevalence of dementia in Istanbul

2b. Features distinguishing this cohort from other population cohorts

Door to door survey

3a. i) Number of publications that involve use of cohort to date

4

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment

Age in years from: 70

To ('until death' if applicable): until death

4b. Study criteria: inclusion criteria

Only community dwelling individuals

4c. Study criteria: exclusion criteria

Subjects with severe communication (ie, aphasia or no knowledge of Turkish) and perceptual (ie, deafness or blindness) problems were excluded from the study.

5. Size of the cohort (i.e. number of participants enrolled)

1,000 – 5,000 participants

6a. Measures used to characterise participants

MMSE, neuropsychological evaluation, DSM IV, NINCDS-ADRDA, CDR

6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

Demented or not

7. Study design

- Prospective cohort
- Cross sectional survey

8. Cases matched by

- Age
- Sex
- Cognitive function

9a. Does the study include a specialised subset of control participants

Yes

9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date

01-10-1999

10a. ii) Data collection end date
10a iii) Data collection for this study is

Closed to new patients

10b. Plans to continue the cohort study beyond the current projected end date
11. Data collected

- Only through the study

12. System in place to enable re-contact with patients for future studies

No

13a. Format and availability of data stored in a database

	Yes/No	% available
Data summarised in database	yes	100
Database is web-based	no	
Database on spreadsheet	yes	100
Database is on paper	no	
Other (specify)		

Language used:

Turkishh and English

13b. Format and availability of data held as individual records

	Yes/No	% available
Data held as individual records	no	
Data is web-based	no	
Data held on computer based records	yes	100
Data held on cards	no	
Other (specify)		

Language used:

Turkish and English

14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

- Apply to PI or co-ordinator at resource

15. Data sharing policy specified as a condition of use

No policy exists

16a. Are tissues/samples/DNA available to other groups

No

16b. i) Description of available tissues/samples/DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
17. Is information on biological characteristics available to other groups

- No